Collegium Pharma (COLL) Misses Q4 EPS by 1c

Collegium Pharma (Nasdaq: COLL) reported Q4 EPS of ($0.46), $0.01 worse than the analyst estimate of ($0.45).

Financial Outlook

Based on our current operating plans, Collegium expects that its existing cash resources, along with the net proceeds of its January 2016 follow-on offering, will fund its operations into 2018.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Financial Select Sector SPDR ETF (XLF) spreader of 20K contracts of July 31 weekly 57 and 59 calls into bank earnings season
• Goldman Sachs reports global fund inflows for week of July 8